Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?


Kocyigit D. , YALÇIN M. U. , Gurses K. M. , Tokgozoglu L. , KARABUDAK R.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.27, ss.276-280, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.msard.2018.11.006
  • Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS
  • Sayfa Sayıları: ss.276-280

Özet

Background: Fingolimod, a sphingosine-1-phosphate receptor agonist, is used for treatment of relapsing-remitting multiple sclerosis (RRMS). S1P receptors that fingolimod acts upon have also been shown to be expressed on atrial myocytes. This expression pattern has been linked with the drug's cardiovascular effects, such as bradycardia. We aimed to evaluate the clinical and electrocardiographic predictors of heart rate (HR) reduction in patients receiving first-dose fingolimod.